Archive for 2001

Benchmarks articles from the selected year appear below. To view articles from previous years, use the links to the left, and select the year you wish to see.

Digital Mammography in the 21st Century

Digital Mammography in the 21st Century

On September 4, 2001, the National Cancer Institute (NCI) and the American College of Radiology Imaging Network (ACRIN) launched a multicenter study to determine if digital mammography meets or exceeds capabilities, costs, benefits, and other factors, when compared to standard film mammography for the detection of breast cancer. Digital mammography is a technique for recording x-ray images in computer code instead of on x-ray film, as with conventional mammography. The images are displayed on a computer monitor (sometimes referred to as a workstation or viewbox) and can be enhanced before they are printed on film.

Imaging Beyond Mammography

Digital Mammography in the 21st Century

Imaging research supported by the National Cancer Institute (NCI) is advancing on several fronts. Besides efforts to improve conventional and digital X-ray mammography, NCI also supports research for several other technologies such as magnetic resonance imaging (MRI), ultrasonography, positron emission tomography (PET), and single photon emission computed tomography (SPECT).

Moving Immunotoxins from Bench to Bedside

Moving immunotoxins from bench to bedside

In the July 26 issue of the New England Journal of Medicine, NCI scientists published the extremely promising results of a recent Phase I clinical trial for hairy cell leukemia, which accounts for about 2 percent of all leukemias in the United States. BenchMarks recently sat down with three of the leaders of the research team to discuss the results and their implications. They are: Ira Pastan, M.D., chief of NCI’s Laboratory of Molecular Biology; David FitzGerald, Ph.D., who heads the Biotherapy Section of the Laboratory of Molecular Biology; and Robert Kreitman, M.D., who heads the Clinical Immunotherapy Section of the Laboratory of Molecular Biology and who directed the clinical trial as principal investigator.